Killing drug ads won’t lower prices — it will kill innovation
Photo by Andrew Harnik/Getty Images
The answer to the problems in American health care isn’t more government. It’s less. Expected profitability drives investment in biomedical research. Imposing new advertising bans or European-style price controls would mean lower-quality care, higher mortality, and the erosion of America’s leadership in medical innovation.
The United Kingdom offers a warning. Once a global leader, it drove investment offshore through overregulation and rigid price controls. Today, only 37% of new medicines are made fully available for their licensed uses in Britain. Americans spend more, but they also live longer: U.S. cancer patients outlive their European counterparts for a reason.
Discovering new drugs is hard. Every breakthrough begins with the freedom to imagine, to compete, and to communicate. Strip companies of the ability to inform patients, and you strip away the incentive to develop the next cure. Competitive markets — not centralized control — will fuel tomorrow’s medical miracles.
Leave a Reply
You must be logged in to post a comment.